Floatz logo

Vorolanib

Refractory Thoracic Tumors

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Refractory Thoracic Tumors cohort.

Asset / SponsorPhaseRating
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B
Docetaxel
Phase 3B
HYPERICUM
Phase 3B
Nivolumab
M.D. Anderson Cancer Center
Phase 1/2CCC
Catequentinib
JIANYANG WANG
Phase 2CCC

View all 23 →

Same molecule, other indications

Vorolanib is also rated in:

renal cell carcinomaDormant
B
Indicative ·
61 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →